Acumen Pharmaceuticals Inc
For the period ended Mar 31, 2024. Filed May 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 14, 2024
ABOS$0.23-3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities | ||
| Net loss | $(14,873) | $(11,307) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 16 | 14 |
| Stock-based compensation expense | 2,484 | 1,390 |
| Amortization of premiums and accretion of discounts on marketable securities, net | (1,763) | (334) |
| Change in fair value of embedded derivatives | 50 | — |
| Amortization of right-of-use asset | 28 | 38 |
| Realized gain on marketable securities | (2) | — |
| Non-cash interest expense | 268 | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (226) | (899) |
| Other assets | 35 | (44) |
| Accounts payable | 1,700 | (878) |
| Accrued clinical trial expenses | (2,020) | 2,486 |
| Accrued expenses and other current liabilities | (3,512) | (603) |
| Finance lease liability | (23) | — |
| Operating lease liability | (21) | (38) |
| Net cash used in operating activities | (17,859) | (10,175) |
| Cash flows from investing activities | ||
| Purchases of marketable securities | (45,292) | (52,131) |
| Proceeds from maturities and sales of marketable securities | 36,100 | 10,204 |
| Purchases of property and equipment | (11) | — |
| Net cash used in investing activities | (9,203) | (41,927) |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock, net of issuance costs | 7,938 | — |
| Payment for financing lease | (739) | — |
| Payments for deferred offering costs | (60) | — |
| Repurchase of common shares to pay employee withholding taxes | (32) | — |
| Net cash provided by financing activities | 7,107 | — |
| Net change in cash and cash equivalents and restricted cash | (19,955) | (52,102) |
| Cash and cash equivalents and restricted cash at the beginning of the period | 67,119 | 130,101 |
| Cash and cash equivalents and restricted cash at the end of the period | $47,164 | $77,999 |
| Supplemental disclosure of cash flow information | ||
| Cash paid for income taxes | $— | $— |
| Cash paid for interest | $756 | $— |
| Supplemental disclosure of noncash investing and financing activities | ||
| Deferred offering costs in accrued expenses and other current liabilities | $78 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.